Condition: Malignant Melanoma · Sponsor: Assistance Publique - Hôpitaux de Paris
Prevention of melanoma can be efficient but mortality remains unchanged and 15 to 20% of patients still die from melanoma. Indeed metastatic melanoma is a heterogeneous highly and multiple mutations driven cancer. Significant survival benefit was demonstrated since 2011 with anti-CTLA4 +/- programmed death-1 (anti PD1) antibodies, B-Raf proto-oncogene, serine/threonine kinase (BRAF) and MAP-ERK kinase (MEK) inhibitors. Future improvement of advanced melanoma prognosis will rely on clinico-epidemiological studies and on biological studies to validate and identify new prognostic and predictive factors based on clinico-epidemiological and histological data, genomic host and tumor alterations, tumor microenvironment characteristics, individual immunological profile and functional imaging. In the context of marketing of costly innovative molecules, prospective collection of economic data on treatment and toxicity are required. Large biobanks collecting data from cohorts of advanced melanoma are mandatory for such projects. MELBASE is a French prospective national cohort enrolling advanced melanoma patients whose objectives are to : * provide an annual instrument panel with descriptive and correlative analysis of advanced melanoma patients in France including epidemiological, clinical, biological and economic characteristics * validate and identify new clinical, epidemiological, and biological prognostic factors such as genomic host and tumor alterations, tumor microenvironment c…
This description comes directly from the study's public registry record.
Celeste Lebbe, MD, PhD · +33142494679 · celeste.lebbe@aphp.fr
Laetitia Da Meda · +33142499392 · laetitia.da-meda@aphp.fr
Always discuss trial participation with your own doctor first.
| CHU d'Amiens | Amiens, France | Recruiting |
| CH Annecy Genevois | Annecy, France | Recruiting |
| CHU de Besançon | Besançon, France | Recruiting |
| Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes | Bobigny, France | Recruiting |
| CHU de Bordeaux Hôpital Haut Levêque | Bordeaux, France | Active Not Recruiting |
| CHU de Bordeaux Hôpital Saint-André | Bordeaux, France | Recruiting |
| Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré | Boulogne-Billancourt, France | Active Not Recruiting |
| CHU de Brest | Brest, France | Recruiting |
| CHU de Caen | Caen, France | Active Not Recruiting |
| Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor | Créteil, France | Recruiting |
| CHU de Dijon | Dijon, France | Recruiting |
| CHU de Grenoble | Grenoble, France | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02828202